• Skip to main content
  • Skip to primary sidebar
Transfusion News
  • About Us
  • Topics
    • Adverse Events (non-infectious)
    • Blood Donation
    • Cell Therapy
    • Coagulation & Plasma Transfusion
    • Platelet Transfusion
    • Policy and Guidelines
    • Quality Control and Regulatory
    • RBC Transfusion
    • Serology/Genotyping
    • Special Transfusion Situations
    • Transfusion Transmitted Infections
  • Continuing Education
  • Archives
  • Podcasts
  • Question of the Day
  • Search
  • Subscribe to Email Alerts
  • Follow us on
  • Search
  • Subscribe to Email Alerts

New Erythropoietin Gene Variants Linked to Hereditary Erythrocytosis

May 7, 2025

Erythrocytosis, a condition marked by the overproduction of red blood cells (RBCs), can be either congenital or acquired. Erythropoietin (EPO), the primary hormone regulating RBC production, is controlled by a tightly regulated negative feedback loop. Under hypoxic conditions, the EPO promoter is activated, leading to increased transcription of the EPO locus resulting in increased production of EPO and subsequent rise in RBCs. Although mutations in genes within this oxygen-sensing pathway may lead to hereditary erythrocytosis, the exact molecular mechanism often remains unclear. In a recent study, researchers sequenced the EPO locus and related hypoxia-pathway genes from six families (29 patients) with unexplained erythrocytosis. They identified three genetic variants in noncoding regions of EPO—one in the promoter and two different variants in intron 1. All three variants showed increased expression in cell lines under hypoxic conditions, had distinct biochemical and pH profiles similar to fetal liver-derived EPO, and had enhanced activity compared to healthy controls. The study also identified new regulatory regions of the EPO promoter, which may lead to new therapies to regulate EPO expression. Further investigation into novel variants of the EPO locus and other genes in the oxygen-sensing EPO pathway is needed.

References:

References:

  1. McMullin MF. Erythrocytosis and variants of EPO. N Engl J Med 2025;392:1742-1745
  2. Maric MD, Idriss S, Delamare M, Le Roy A, et al. Identification of hepatic-like EPO as a cause of polycythemia. N Engl J Med 2025;392:1684-1697

Filed Under

  • News
  • Special Transfusion Situations

Recommended

  • Hypovolemic Phlebotomy Reduces Transfusions During Liver Surgery

  • New Draft FDA Guidance to Reduce the Risk of HIV Transfusion-Transmission Using Individual Risk-Based Questions

  • Transfusions with Whole Blood Compared to Packed Red Cells for African Children with Severe Anemia

Show Comments

Reader Interactions

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Get the latest news. Subscribe to our mailing list. Sign Up

Primary Sidebar

Latest News

  • New Erythropoietin Gene Variants Linked to Hereditary Erythrocytosis

  • Multifaceted Threats to the Blood Supply from Climate Change

  • Distinct Roles for Differently Aged Platelets

  • Anemia Treatment Bundle Improves Hemoglobin Recovery after Critical Illness

    Question of the Day

    Copyright © 2025 John Wiley & Sons, Inc. All Rights Reserved.
    Privacy Policy

    Association for the Advancement of Blood and Biotherapies Wiley